Isolators, RABS, and What I Re-learned About Microbiology

About 25 years ago, I was working in aseptic operations using the technology and practices common at the time. Isolators were not yet widely adopted, and RABS were not prevalent across the industry. What we had instead were open processes, strong reliance on cleanroom classification, and most importantly, discipline.

Aseptic processing in those days was fundamentally human centered. Gowning mattered. Movement mattered. Technique mattered. You could feel the risk in the room because outcomes were directly tied to how people behaved. Engineered barriers were not yet part of the standard toolkit, so performance lived and died with execution.

Fast forward to today, and the conversation has shifted.

Recently, at the 2026 ISPE Aseptic Conference, I was seated as a participant while a panel discussed the evolution of aseptic technologies, specifically the role of RABS and isolators. The discussion was led by experienced practitioners who have spent their careers advancing these systems in real operating environments.

As I listened, I found myself reflecting on a simple question. Have we fundamentally changed the problem, or have we changed how we manage it?

The panel outlined the advantages of both approaches. RABS provide a balance of access and protection. Isolators prioritize separation and repeatability. Both are valid. Both are proven. But they are built on different assumptions about risk.

What stood out to me was not just the content of the discussion, but the questions it triggered.

• Why do we validate to certain log reductions?
• How do biological indicators actually function?
• Do microorganisms behave the way we often simplify them in cleanroom conversations?
• What is the true mechanism by which contamination moves and persists?

While the panel continued, I explored these questions in parallel using AI. This was not about challenging the experts on stage. It was about reconnecting with the fundamentals and testing my own assumptions in real time.

That exercise reinforced several points that are easy to lose sight of.

First, microorganisms in cleanrooms are rarely free floating. They are typically carried on particles such as skin flakes, dust, and droplets. Control the particles, and you control the dominant pathway of microbial risk. That was true 25 years ago. It is still true today. At the same time, airflow patterns, surface interactions, and environmental conditions still play important roles and cannot be ignored.

Second, not all microorganisms behave the same way. Many vegetative cells are fragile and short lived, particularly when dried, but some organisms can persist longer than expected depending on conditions. Spores, however, are fundamentally different. They are designed to persist. They remain dormant, resistant, and capable of returning to an active state when conditions allow.

This is why our validation strategies are built around them.

We do not rely on real world contamination levels to validate lethality. Instead, we demonstrate capability. We challenge our systems with highly resistant spores, often on standardized carriers, and confirm that we can achieve what is commonly referred to as a six-log reduction under defined conditions. This demonstrates a validated kill capability, not sterility itself. Not because it reflects reality, but because it exceeds it.

If you can consistently eliminate the most resistant form of life under worst case conditions, you create margin. And margin is what protects patients.

Viewed through that lens, the distinction between RABS and isolators becomes more direct, but it should not be overstated. In practice, performance is not determined solely by whether a system is labeled RABS or isolator, but by how well it is designed, integrated, and operated. A well designed and well operated RABS can deliver strong performance, just as a poorly designed isolator can introduce risk. The technology matters, but execution ultimately determines outcomes.

One of the most important elements of that execution is design. An isolator with a poorly designed interior can introduce risk just as a well-designed system can reduce it. Cleanability matters. Are there gaps, dead legs, or shadowed areas where contamination can settle? Can the decontamination agent reliably reach every surface? These are not theoretical concerns; they are practical realities that determine whether a system performs as intended.

This is where engineering discipline and microbiology intersect. The effectiveness of a decontamination cycle is only as strong as the accessibility and design of the surfaces it is meant to treat.

RABS reduce risk, but they still depend on people. Their performance is tied to operator discipline, consistency, and decision making. That is a variable system by definition.

Isolators take a different path. They are designed to remove that variability by creating a closed environment and relying on repeatable, validated decontamination cycles. That is a controlled system by design.

Both approaches can be effective. The real question is how you choose to manage variability.

Sitting in that room, listening and exploring in parallel, I was reminded that the industry has not changed its objective. We are still trying to control particles. We are still trying to manage microbial survival and growth. We are still trying to reduce variability in a process where failure is not acceptable.

What has changed is our willingness to engineer that variability out of the system.

For me, the value of that experience was not in choosing a side. It was in reconnecting the technology to the biology and in using modern tools to deepen that understanding in real time.

There is also a broader takeaway for how we learn as an industry.

Sitting in a conference session should not be a passive activity. The real value comes when you engage actively. Listen, but also question. Follow those questions. Explore the edges of what you are hearing. Today, tools like AI make that possible in real time.

That said, not all AI is equal. The quality of insight is directly tied to the quality of the information behind it. AI grounded in curated, expert knowledge will always outperform generic models trained on broad, unfiltered data.

This is an area where the industry has an opportunity. Organizations like ISPE are uniquely positioned to bring together expert knowledge and make it more accessible. The ability to pair that curated knowledge base with modern AI tools has the potential to significantly elevate how professionals learn, question, and apply what they know.

And this is where the broader value becomes clear.

ISPE creates a platform where this kind of learning happens. You hear from practitioners. You reflect on your own experience. You test assumptions. You extend your thinking. Knowledge is not simply delivered. It is actively shared, challenged, and built upon.

Because in the end, this is not a debate about isolators or RABS.

It is a leadership question.

How much variability are you willing to accept, and where do you choose to control it?

There is also a call to action here for all of us in the industry.

Do not sit passively in training sessions or conference presentations. Engage. Ask questions. Follow the threads that matter to you. Use the tools available to you, including AI, to deepen your understanding in real time. But do so thoughtfully, recognizing that AI is only as strong as the information behind it.

And importantly, help shape what comes next.

At ISPE, we are working diligently toward enabling access to expert curated knowledge in ways that can be paired with modern AI tools. The goal is not just more information, but better, more reliable insight delivered in a way that helps professionals think more clearly and act more effectively.

That future is within reach, but it will only be as strong as the collective knowledge we contribute and the engagement we bring.

So lean in. Participate. Contribute.

Because the next evolution of our industry will not just be built on technology. It will be built on how well we learn.